Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
Covid Vaccine
March 11, 2022
Two years ago, the World Health Organization (WHO) declared COVID-19 a “pandemic.” We look back at key activities from BIO and the biopharmaceutical industry—and where we go from here.
Support Ukraine
March 8, 2022
Adding to the wide-scale human suffering across Ukraine, Russia’s unprovoked invasion of Ukraine is causing a major disruption to both medical as well as agricultural supply chains in the region and worldwide. As…
heart disease
February 24, 2022
Heart disease is the leading cause of death in America. During American Heart Month, we explore how to improve cardiovascular disease outcomes. “Heart disease costs our healthcare system $216 billion dollars annually,…
Press Releases
June 14, 2022
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term. BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention hosted by BIO in San Diego, June 13-16, 2022. “On…
June 13, 2022
The third annual report that examines diversity, equity, and inclusion (DEI) in the biotechnology industry launched today at the 2022 BIO International Convention. The report, “Measuring Diversity in the Biotech Industry: Tracking Progress in Small and Large Companies”, investigates the state of…
June 14, 2022
The licensing of university and nonprofit research has made a significant contribution to US gross domestic product (GDP), industrial gross output, and jobs over the last 25 years and underscores the importance of basic and applied research to the US economy, as well as the demand for public…
Letters, Comments & Testimony
June 12, 2022
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic…
June 15, 2022
The Biotechnology Innovation Organization (BIO), BIO members and State affiliates urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect earlier this year. The 2017 Tax Cuts and Jobs Act (TCJA) changed the longstanding deduction for R&D…
May 5, 2022
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Federal Trade Commission’s (FTC’s or the Commission’s) Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and…
Join BIOAction
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.